Katharina Kircanski1, Joelle LeMoult2, Sarah Ordaz3, Ian H Gotlib2. 1. Department of Psychology, Stanford University, United States. Electronic address: kircanskik@mail.nih.gov. 2. Department of Psychology, Stanford University, United States. 3. Department of Psychology, Stanford University, United States; Department of Psychiatry, Stanford University, United States.
Abstract
BACKGROUND: Although approximately half of adults diagnosed with a depressive or anxiety disorder exhibit their simultaneous co-occurrence, traditional research has centered on single-target diagnoses, overlooking comorbidities within samples. In this article, we review and extend the literature that directly investigates co-occurring depression and anxiety, with the goal of shifting the focus from co-occurring diagnoses to symptom dimensions. METHODS: First, we review studies that have directly compared psychobiological features (neural, neuroendocrine, autonomic) across depression, anxiety, and their co-occurrence, defined either categorically or dimensionally. Second, we analyze adults' diurnal cortisol secretion to examine the independent and interactive relations of continuously-assessed depressive and anxiety symptoms to neuroendocrine function. RESULTS: Previous findings on the psychobiology of diagnostic co-occurrence are mixed. While nascent, evidence from dimensionally focused studies suggests that co-occurring levels of depressive and anxiety symptoms can interact with one another, as reflected in a distinct psychobiological profile for individuals with high levels of both symptom dimensions. Results of our analyses support this formulation: we found that depressive and anxiety symptom dimensions interacted consistently in their relation to the measures of diurnal cortisol. LIMITATIONS: The illustrative sample was relatively small and included only women; future research should examine generalizability of these findings. CONCLUSIONS: A dimensional approach to investigating the psychobiology of co-occurring depression and anxiety affords both conceptual and practical advantages. Simultaneously assessing depressive and anxiety symptom dimensions can efficiently capture their unique, shared, and interactive features, thereby identifying targets for intervention across a wide range of symptom presentations. Published by Elsevier B.V.
BACKGROUND: Although approximately half of adults diagnosed with a depressive or anxiety disorder exhibit their simultaneous co-occurrence, traditional research has centered on single-target diagnoses, overlooking comorbidities within samples. In this article, we review and extend the literature that directly investigates co-occurring depression and anxiety, with the goal of shifting the focus from co-occurring diagnoses to symptom dimensions. METHODS: First, we review studies that have directly compared psychobiological features (neural, neuroendocrine, autonomic) across depression, anxiety, and their co-occurrence, defined either categorically or dimensionally. Second, we analyze adults' diurnal cortisol secretion to examine the independent and interactive relations of continuously-assessed depressive and anxiety symptoms to neuroendocrine function. RESULTS: Previous findings on the psychobiology of diagnostic co-occurrence are mixed. While nascent, evidence from dimensionally focused studies suggests that co-occurring levels of depressive and anxiety symptoms can interact with one another, as reflected in a distinct psychobiological profile for individuals with high levels of both symptom dimensions. Results of our analyses support this formulation: we found that depressive and anxiety symptom dimensions interacted consistently in their relation to the measures of diurnal cortisol. LIMITATIONS: The illustrative sample was relatively small and included only women; future research should examine generalizability of these findings. CONCLUSIONS: A dimensional approach to investigating the psychobiology of co-occurring depression and anxiety affords both conceptual and practical advantages. Simultaneously assessing depressive and anxiety symptom dimensions can efficiently capture their unique, shared, and interactive features, thereby identifying targets for intervention across a wide range of symptom presentations. Published by Elsevier B.V.
Authors: Stewart A Shankman; Brady D Nelson; Casey Sarapas; E Jenna Robison-Andrew; Miranda L Campbell; Sarah E Altman; Sarah Kate McGowan; Andrea C Katz; Stephanie M Gorka Journal: J Abnorm Psychol Date: 2012-11-12
Authors: Sophie A Vreeburg; Frans G Zitman; Johannes van Pelt; Roel H Derijk; Jolanda C M Verhagen; Richard van Dyck; Witte J G Hoogendijk; Johannes H Smit; Brenda W J H Penninx Journal: Psychosom Med Date: 2010-02-26 Impact factor: 4.312
Authors: Gavin Andrews; Megan J Hobbs; Thomas D Borkovec; Katja Beesdo; Michelle G Craske; Richard G Heimberg; Ronald M Rapee; Ayelet Meron Ruscio; Melinda A Stanley Journal: Depress Anxiety Date: 2010-02 Impact factor: 6.505
Authors: Damijan Knez; Natalia Colettis; Luca G Iacovino; Matej Sova; Anja Pišlar; Janez Konc; Samo Lešnik; Josefina Higgs; Fabiola Kamecki; Irene Mangialavori; Ana Dolšak; Simon Žakelj; Jurij Trontelj; Janko Kos; Claudia Binda; Mariel Marder; Stanislav Gobec Journal: J Med Chem Date: 2020-01-22 Impact factor: 7.446
Authors: Christopher G Kemp; Leslie C M Johnson; Rajesh Sagar; Subramani Poongothai; Nikhil Tandon; Ranjit Mohan Anjana; Sosale Aravind; Gumpeny R Sridhar; Shivani A Patel; Karl Emmert-Fees; Deepa Rao; K M V Narayan; Viswanathan Mohan; Mohammed K Ali; Lydia A Chwastiak Journal: Gen Hosp Psychiatry Date: 2021-11-27 Impact factor: 3.238
Authors: Anne Campbell; Steffani R Bailey; Kim A Hoffman; Javier Ponce-Terashima; Katie Fankhauser; Miguel Marino; Dennis McCarty Journal: J Psychoactive Drugs Date: 2020-04-15
Authors: Lisa M Christian; Shannon Webber; Shannon Gillespie; Anna M Strahm; Jonathan Schaffir; Yevgeniya Gokun; Kyle Porter Journal: Sleep Date: 2021-11-12 Impact factor: 6.313